Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | Early results from INCB123667 in cyclin E1 overexpressing/CCNE1-amplified cancers

Matteo Simonelli • 16 Sep 2024
ESMO 2024
General INCB123667

Matteo Simonelli, MD, IRCCS Istiuto Nazionale Tumori Regina Elena (IRE), Rome, Italy, discusses the Phase I trial (NCT05238922) of INCB123667, a selective CDK2 inhibitor, in patients with advanced solid tumors, particularly those with cyclin E1 overexpression or CCNE1 amplification. INCB123667 was generally well tolerated, especially in patients with ovarian cancer, with common treatment-related adverse events including thrombocytopenia, nausea, and anemia. Promising antitumor activity was observed, and ongoing trials will further evaluate the drug in specific tumor cohorts. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Matteo Simonelli

KANDLELIT-001: MK-1084 monotherapy in KRAS G12C-mutated solid tumors
2:10
KANDLELIT-001: MK-1084 monotherapy in KRAS G12C-mutated solid tumors
Matteo Simonelli • 20 Oct 2025
Advancements in developing inhibitors for non-G12C KRAS mutations
0:38
Advancements in developing inhibitors for non-G12C KRAS mutations
Matteo Simonelli • 20 Oct 2025
KANDLELIT-001: MK-1084 monotherapy in KRAS G12C- mutated advanced solid tumors
2:10
KANDLELIT-001: MK-1084 monotherapy in KRAS G12C- mutated advanced solid tumors
Matteo Simonelli • 20 Oct 2025
Treating cyclin E1 overexpressing/CCNE1-amplified cancers with INCB123667
0:50
Treating cyclin E1 overexpressing/CCNE1-amplified cancers with INCB123667
Matteo Simonelli • 16 Sep 2024

Related Videos

Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026
5-year toxicity following SABR: insights from the SABR-5 trial
0:42
5-year toxicity following SABR: insights from the SABR-5 trial
Robert Olson • 16 May 2026
How should results from the SABR-5 trial guide future SABR studies?
1:05
How should results from the SABR-5 trial guide future SABR studies?
Robert Olson • 16 May 2026
The gut microbiome as a prognostic marker of side effects following radiotherapy
0:45
The gut microbiome as a prognostic marker of side effects following radiotherapy
Miguel Reis Ferreira • 16 May 2026
The content of VJOncology is intended for healthcare professionals